Elevai Labs
ELAB
2 hedge funds and large institutions have $4.06K invested in Elevai Labs in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
1.01% less ownership
Funds ownership: 1.13% → 0.11% (-1%)
50% less funds holding
Funds holding: 4 → 2 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
94% less capital inflows, than outflows
Capital inflows: $3.21K | Capital outflows: $54.8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.6K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$1.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$38.5K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$11.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.81K |
ELAB Hedge Fund Activity: Q3 2025 in Review
2 of the 7,658 institutional investors tracked by Wall St. Rank reported a position in Elevai Labs (ELAB) for Q3 2025, worth a combined $4.06K — down 93% from $57.7K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ELAB and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Citigroup, opening a new position worth an estimated $1.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $38.5K sold.
- 2 institutional investors held Elevai Labs (ELAB) as of Q3 2025, down from 4 in Q2 2025.
- Funds reported $4.06K of Elevai Labs stock for Q3 2025, down 93% quarter-over-quarter.
- 1 fund opened new Elevai Labs positions in Q3 2025 and 3 closed out, a net change of -2 holders.
- The largest Elevai Labs buyer in Q3 2025 was Citigroup, an estimated $1.6K added.
- The largest Elevai Labs seller in Q3 2025 was Citadel Advisors, an estimated $38.5K sold.
Based on aggregated 13F filings for Q3 2025.